Indian Journal of Ophthalmology (Jan 2022)

Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19

  • Maria Eduarda Andrade e Andrade,
  • Juliane Cardoso Rodrigues,
  • Elvio Ferreira Junior,
  • Mario Henrique Camargos de Lima

DOI
https://doi.org/10.4103/ijo.IJO_1021_22
Journal volume & issue
Vol. 70, no. 8
pp. 3134 – 3136

Abstract

Read online

This report shows a case of corneal transplant rejection after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), short after receiving the BNT162b2 vaccine, in a patient who had undergone keratoplasty more than 20 years ago, with no previous episodes of rejection and no other factor that could lead to the findings on his examinations. After treatment with high doses of topic, oral, and sub-conjunctival corticoids, the patient had a favorable therapeutic response. The signs of corneal transplant rejection must be oriented to the patients and the causing factors actively searched by ophthalmologists so that treatment is rapidly initiated and sequels are avoided. This report raises the question if these events are correlated and whether the patient should receive the second dose of the vaccine against SARS-CoV-2 or not.

Keywords